Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$680M |
| 2 |
Microsoft
MSFT
|
+$506M |
| 3 |
UnitedHealth
UNH
|
+$393M |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$381M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$348M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.24B |
| 2 |
Tesla
TSLA
|
+$450M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$444M |
| 4 |
TSMC
TSM
|
+$432M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$371M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 1.79% |
| 2 | Consumer Discretionary | 0.82% |
| 3 | Financials | 0.79% |
| 4 | Healthcare | 0.66% |
| 5 | Industrials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
12076
CALL
Reading International Class A
RDI
$43.5M
| $56.3K | ﹤0.01% |
+42,000
| New | +$55.9K |
|
12077
CEMIG Preferred Shares
CIG
$5.69B
| $56.3K | ﹤0.01% |
28,703
-64,618
| -69% | -$118K |
|
12078
PUT
Heron Therapeutics
HRTX
$59.1M
| $56.1K | ﹤0.01% |
+27,100
| New | +$55.3K |
|
12079
ClearSign Technologies
CLIR
$32.2M
| $55.7K | ﹤0.01% |
10,410
+3,321
| +47% | +$20K |
|
12080
Anixa Biosciences
ANIX
$125M
| $55.5K | ﹤0.01% |
16,803
-178,368
| -91% | -$510K |
|
12081
PUT
W&T Offshore
WTI
$540M
| $55.3K | ﹤0.01% |
33,500
+19,000
| +131% | +$28K |
|
12082
CALL
Westwater Resources
WWR
$77.1M
| $55.3K | ﹤0.01% |
92,100
-62,400
| -40% | -$32.8K |
|
12083
CALL
Blink Charging
BLNK
$86.4M
| $54.9K | ﹤0.01% |
58,400
+28,500
| +95% | +$22.8K |
|
12084
CALL
Neuronetics
STIM
$226M
| $54.8K | ﹤0.01% |
+15,700
| New | +$62K |
|
12085
PUT
Ardagh Metal Packaging
AMBP
$3.12B
| $54.8K | ﹤0.01% |
+12,800
| New | +$46.4K |
|
12086
PetMed Express
PETS
$39M
| $54.3K | ﹤0.01% |
16,346
-158,905
| -91% | -$566K |
|
12087
CALL
Bionano Genomics
BNGO
$14.7M
| $53.8K | ﹤0.01% |
16,400
-1,100
| -6% | -$4.1K |
|
12088
CALL
Monte Rosa Therapeutics
GLUE
$1.22B
| $53.2K | ﹤0.01% |
11,800
-22,400
| -65% | -$99.9K |
|
12089
CALL
NanoViricides
NNVC
$32.7M
| $53.2K | ﹤0.01% |
38,000
+23,200
| +157% | +$31.7K |
|
12090
CALL
Ring Energy
REI
$362M
| $53.2K | ﹤0.01% |
67,300
+25,000
| +59% | +$21.2K |
|
12091
CALL
ProQR Therapeutics
PRQR
$326M
| $53K | ﹤0.01% |
26,000
-500
| -2% | -$813 |
|
12092
PUT
Cardlytics
CDLX
$24.9M
| $52.8K | ﹤0.01% |
3,200
-4,950
| -61% | -$85.5K |
|
12093
PUT
Xeris Biopharma Holdings
XERS
$1.6B
| $52.8K | ﹤0.01% |
11,300
-2,300
| -17% | -$10.5K |
|
12094
CALL
Oramed Pharmaceuticals
ORMP
$223M
| $52.6K | ﹤0.01% |
+23,400
| New | +$51.6K |
|
12095
Marine Petroleum Trust
MARPS
$9.84M
| $52.6K | ﹤0.01% |
11,486
+88
| +0.8% | +$361 |
|
|
DDL
12096
Dingdong
DDL
$503M
| $52.3K | ﹤0.01% |
+25,915
| New | +$58.5K |
|
12097
Acrivon Therapeutics
ACRV
$90.4M
| $52.2K | ﹤0.01% |
43,860
+29,280
| +201% | +$40.2K |
|
|
HUYA
12098
CALL
Huya Inc
HUYA
$491M
| $52.1K | ﹤0.01% |
14,800
-5,100
| -26% | -$18.5K |
|
|
CCIXW
12099
DELISTED
Churchill Capital Corp IX Warrant
CCIXW
| $52.1K | ﹤0.01% |
+52,075
| New | +$49K |
|
12100
Offerpad Solutions
OPAD
$21.6M
| $52.1K | ﹤0.01% |
5,722
+3,480
| +155% | +$40.1K |
|
Similar funds
Jeff Yass's Q2 2025 Portfolio in Review
As of Q2 2025, Jeff Yass held 14,080 positions worth $720B, up 23% from $586B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Jeff Yass deployed $32.3B of net new capital in Q2 2025, opening 1,720 new positions and adding to 5,716 existing holdings. Its largest new stake was iShares Core MSCI Total International Stock ETF: 1,549,778 shares worth $120M.
By sector, the portfolio is most concentrated in Technology at 1.8% of assets, up from 1.6% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $5.24B trimmed.
- Jeff Yass's largest Q2 2025 buy was iShares Core MSCI Total International Stock ETF: 1,549,778 shares worth $120M.
- Jeff Yass added most to Apple in Q2 2025, an estimated $680M increase.
- Jeff Yass's biggest Q2 2025 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.24B.
- Jeff Yass fully exited Vanguard Intermediate-Term Bond ETF in Q2 2025, selling an estimated $61.8M.
- Jeff Yass's ten largest holdings make up 26% of its $720B portfolio in Q2 2025.
- Jeff Yass opened 1,720 new positions and closed 1,538 in Q2 2025.
- Jeff Yass's portfolio value rose 23% quarter-over-quarter to $720B.
Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.